Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bolar investor litigation

Executive Summary

Aug. 4 complaint by investor Martin Bergstein alleges firm violated federal securities laws and engaged in fraud and "other misrepresentations." The plaintiff seeks unspecified damages for himself "and all other persons who during the period Aug. 21, 1987 to Aug. 3, 1989 purchased" Bolar stock. In an Aug. 10 statement, firm said the complaint is based on "the alleged failure" to disclose that its ANDA for a generic version of Dyazide "was fraudulent and questionable." Bolar commented that the allegations "are without merit" and said it will "defend the action vigorously".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel